BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 23857457)

  • 1. Robustness of intratumour ¹⁸F-FDG PET uptake heterogeneity quantification for therapy response prediction in oesophageal carcinoma.
    Hatt M; Tixier F; Cheze Le Rest C; Pradier O; Visvikis D
    Eur J Nucl Med Mol Imaging; 2013 Oct; 40(11):1662-71. PubMed ID: 23857457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intra-tumour 18F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging.
    Dong X; Wu P; Sun X; Li W; Wan H; Yu J; Xing L
    J Med Imaging Radiat Oncol; 2015 Jun; 59(3):338-45. PubMed ID: 25708154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer.
    Tixier F; Le Rest CC; Hatt M; Albarghach N; Pradier O; Metges JP; Corcos L; Visvikis D
    J Nucl Med; 2011 Mar; 52(3):369-78. PubMed ID: 21321270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of regional lymph node status using (18)F-FDG PET/CT parameters in oesophageal cancer patients: comparison of SUV, volumetric parameters and intratumoral heterogeneity.
    Kim SJ; Pak K; Chang S
    Br J Radiol; 2016; 89(1058):20150673. PubMed ID: 26607643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline ¹⁸F-FDG PET image-derived parameters for therapy response prediction in oesophageal cancer.
    Hatt M; Visvikis D; Pradier O; Cheze-le Rest C
    Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1595-606. PubMed ID: 21559979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reproducibility of tumor uptake heterogeneity characterization through textural feature analysis in 18F-FDG PET.
    Tixier F; Hatt M; Le Rest CC; Le Pogam A; Corcos L; Visvikis D
    J Nucl Med; 2012 May; 53(5):693-700. PubMed ID: 22454484
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Lasnon C; Majdoub M; Lavigne B; Do P; Madelaine J; Visvikis D; Hatt M; Aide N
    Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2324-2335. PubMed ID: 27325312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour delineation in oesophageal cancer - A prospective study of delineation in PET and CT with and without endoscopically placed clip markers.
    Thomas L; Lapa C; Bundschuh RA; Polat B; Sonke JJ; Guckenberger M
    Radiother Oncol; 2015 Aug; 116(2):269-75. PubMed ID: 26364886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer with Textural Features Derived from Pretreatment
    Beukinga RJ; Hulshoff JB; van Dijk LV; Muijs CT; Burgerhof JGM; Kats-Ugurlu G; Slart RHJA; Slump CH; Mul VEM; Plukker JTM
    J Nucl Med; 2017 May; 58(5):723-729. PubMed ID: 27738011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy.
    Tan S; Kligerman S; Chen W; Lu M; Kim G; Feigenberg S; D'Souza WD; Suntharalingam M; Lu W
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1375-82. PubMed ID: 23219566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Texture analysis of computed tomography data using morphologic and metabolic delineation of esophageal cancer-relation to tumor type and neoadjuvant therapy response.
    Zhang YH; Herlin G; Rouvelas I; Nilsson M; Lundell L; Brismar TB
    Dis Esophagus; 2019 Apr; 32(4):. PubMed ID: 30295752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detecting interval metastases and response assessment using 18F-FDG PET/CT after neoadjuvant chemoradiotherapy for esophageal cancer.
    Stiekema J; Vermeulen D; Vegt E; Voncken FE; Aleman BM; Sanders J; Boot H; van Sandick JW
    Clin Nucl Med; 2014 Oct; 39(10):862-7. PubMed ID: 25140549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology.
    Hatt M; Visvikis D; Albarghach NM; Tixier F; Pradier O; Cheze-le Rest C
    Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1191-202. PubMed ID: 21365252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?
    Groheux D; Majdoub M; Tixier F; Le Rest CC; Martineau A; Merlet P; Espié M; de Roquancourt A; Hindié E; Hatt M; Visvikis D
    Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1682-1691. PubMed ID: 26140849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased FDG uptake on late-treatment PET in non-tumour-affected oesophagus is prognostic for pathological complete response and disease recurrence in patients undergoing neoadjuvant radiochemotherapy.
    Zschaeck S; Hofheinz F; Zöphel K; Bütof R; Jentsch C; Schmollack J; Löck S; Kotzerke J; Baretton G; Weitz J; Baumann M; Krause M
    Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1813-1822. PubMed ID: 28600646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of pre-therapy (18)F-FDG PET/CT for the outcome of (18)F-FDG PET-guided radiotherapy in patients with head and neck cancer.
    Picchio M; Kirienko M; Mapelli P; Dell'Oca I; Villa E; Gallivanone F; Gianolli L; Messa C; Castiglioni I
    Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):21-31. PubMed ID: 23990143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of tumor size and tracer uptake heterogeneity in (18)F-FDG PET and CT non-small cell lung cancer tumor delineation.
    Hatt M; Cheze-le Rest C; van Baardwijk A; Lambin P; Pradier O; Visvikis D
    J Nucl Med; 2011 Nov; 52(11):1690-7. PubMed ID: 21990577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3).
    Palie O; Michel P; Ménard JF; Rousseau C; Rio E; Bridji B; Benyoucef A; Meyer ME; Jalali K; Bardet S; M'vondo CM; Olivier P; Faure G; Itti E; Diana C; Houzard C; Mornex F; Di Fiore F; Vera P
    Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1345-55. PubMed ID: 23715903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer.
    Heijmen L; de Geus-Oei LF; de Wilt JH; Visvikis D; Hatt M; Visser EP; Bussink J; Punt CJ; Oyen WJ; van Laarhoven HW
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1858-67. PubMed ID: 22945372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of Recurrence and Mortality of Locally Advanced Esophageal Cancer Patients Using Pretreatment F-18 FDG PET/CT Parameters: Intratumoral Heterogeneity, SUV, and Volumetric Parameters.
    Chang S; Kim SJ
    Cancer Biother Radiopharm; 2016 Feb; 31(1):1-6. PubMed ID: 26844846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.